CervoMed Secures $10 Million to Advance Brain Disease Pipeline
BOSTON, June 18, 2026 CervoMed Inc., a clinical-stage biotechnology company focused on developing therapies for age-related neurological disorders, has...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
BOSTON, June 18, 2026 CervoMed Inc., a clinical-stage biotechnology company focused on developing therapies for age-related neurological disorders, has...
Houston, Texas, United States — March 11, 2026 Biotechnology company CNS Pharmaceuticals has announced the launch of a new...
New York, United States — March 10, 2026 Biotechnology company Dianthus Therapeutics has announced the pricing of an upsized...
NEW HAVEN, Connecticut — March 10, 2026 Biotechnology company BioXcel Therapeutics Inc. has announced a registered direct offering expected...
VANCOUVER, British Columbia & BOSTON — March 10, 2026 Global biotechnology company Xenon Pharmaceuticals Inc. has announced the pricing...
New York, United States & Waltham, Massachusetts – March 9, 2026 Dianthus Therapeutics, Inc., a clinical-stage biotechnology company focused...
MONTPELLIER, France | January 28, 2026 — Sensorion, a clinical-stage biotechnology company focused on hearing loss disorders, announced a...
